Study Reveals Previously Unknown Drug-Associated Arrhythmias
To identify medications with potential proarrhythmic association.
To identify medications with potential proarrhythmic association.
On this week’s MPR pod we take a look at the current status of Johnson & Johnson’s COVID-19 vaccine candidate; Considerations in assessing blood donors during pandemic times; A newly approved drug to treat heart failure; Promising results for a potential Alzheimer treatment; And changes declared for vinca alkaloid labeling.
The approval was based on data from the double-blind, placebo-controlled phase 3 VICTORIA trial.
The sNDA is supported by data from the phase 3 EMPEROR-Reduced trial which compared the efficacy and safety of empagliflozin to placebo, in addition to recommended therapy, in 3730 patients with chronic heart failure with reduced ejection fraction.
The recommendation was based on data from the double-blind, parallel-group, active-controlled phase 3 PARAGON-HF trial.
Regular use tied to a 65% risk for cardiovascular death
This week we cover new findings for the diabetes drug sitagliptin in pediatrics; An obesity treatment has its approval expanded; The FDA issue a Complete Response Letter for an outpatient alternative treatment; And news of availability for a transdermal contraceptive patch.
Behavioral counseling interventions to promote healthy diet and physical activity have moderate net benefit
To evaluate the association, the study authors utilized healthcare databases from Ontario, Canada to identify adults 66 years of age and older with no history of AF who filled at least 1 prescription for levothyroxine.
Ertugliflozin is noninferior to placebo for the primary end point of major adverse cardiovascular events.